First of all, although the synergistic effects of Rapa and Osi in treating A549 and PC-9 cells have been affirmed, it is still uncertain whether Rapa overcomes the Osi resistance in NSCLC. This evidence concerns the gene TRERF1 and non-small cell lung carcinoma.